Home
Jounce Therapeutics

Jounce Therapeutics Market Share Analysis for June 2026

Concentra is a biosciences company.

Health > Biotechnology and Pharmaceuticals

Domainjouncetx.com

Year Founded2012

Employees51 - 200

Annual Revenue$75M - $100M

Jounce Therapeutics

Jounce Therapeutics (including company regionals)

jouncetx.com

See more website traffic and engagement information

Jounce Therapeutics Revenue up to June 2026 is 75M - 100M

revenue generated by Jounce Therapeutics top domains

Jounce Therapeutics top domains revenue over 3 years

Revenue for Jounce Therapeutics top domains

jouncetx.com75M - 100M

See more with Sales Intelligence

Total visits to Jounce Therapeutics's top domains

Understand Jounce Therapeutics market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Jounce Therapeutics's top domains

Analyze Jounce Therapeutics engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Jounce Therapeutics's top domains

See how Jounce Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Jounce Therapeutics top competitors by domain

Top similar sites in June 2026, ranked by their affinity

exosomedx.comCompany NameExosome DiagnosticsEmployees51 - 200HQUnited States, Massachusetts, WalthamAnnual revenue$15M - $25MTotal visits2.6KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Jounce Therapeutics

These are the website technologies, by industry, used by Jounce Therapeutics top domains

Social (4)

Instagram

Content Management System (2)

WordPress

Widget (2)

Twemoji

Advertising (1)

PubMatic

More Technologies

9

See all

News & Signals from Jounce Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsJouncetx partnered with Redx Pharma Plc on Feb 1st '23.Concentra's offer comes three weeks after Jounce signed an all-stock merger deal with U.K.-based Redx Pharma, which the companies expect to complete by the second quarter of 2023.

NewsJouncetx is developing JTX-8064 and vopratelimab.Jounce is developing JTX-8064 and vopratelimab as part of its focus on the discovery and development of novel cancer immunotherapies and predictive biomarkers.

NewsJouncetx merged with Redx Pharma Plc on Mar 2nd '23.Jounce Therapeutics ( NASDAQ: JNCE ) is merging with U.K.-based Redx Pharma in an all stock deal after which the combined company will be known as Redx and listed on Nasdaq under the ticker REDX.